These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1140 related articles for article (PubMed ID: 19672093)

  • 21. Evaluation of recombinant allergens Bet v 1 and Bet v 2 (profilin) by Pharmacia CAP system in patients with pollen-related allergy to birch and apple.
    Rossi RE; Monasterolo G; Operti D; Corsi M
    Allergy; 1996 Dec; 51(12):940-5. PubMed ID: 9020425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
    Klimek L; Schendzielorz P; Pinol R; Pfaar O
    Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations.
    Niederberger V; Pauli G; Grönlund H; Fröschl R; Rumpold H; Kraft D; Valenta R; Spitzauer S
    J Allergy Clin Immunol; 1998 Oct; 102(4 Pt 1):579-91. PubMed ID: 9802365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.
    Shirasaki H; Yamamoto T; Koyanagi Y; Watanabe N; Himi T
    Allergol Int; 2008 Mar; 57(1):93-6. PubMed ID: 18209509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoglobulin G4-antibodies to rBet v 1 and risk of sensitization and atopic disease in the child.
    Kihlström A; Hedlin G; Pershagen G; Troye-Blomberg M; Härfast B; Lilja G
    Clin Exp Allergy; 2005 Dec; 35(12):1542-9. PubMed ID: 16393319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of multiple T cell epitopes on Bet v I, the major birch pollen allergen, using specific T cell clones and overlapping peptides.
    Ebner C; Szépfalusi Z; Ferreira F; Jilek A; Valenta R; Parronchi P; Maggi E; Romagnani S; Scheiner O; Kraft D
    J Immunol; 1993 Feb; 150(3):1047-54. PubMed ID: 7678615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous apple consumption induces oral tolerance in birch-pollen-associated apple allergy.
    Kopac P; Rudin M; Gentinetta T; Gerber R; Pichler Ch; Hausmann O; Schnyder B; Pichler WJ
    Allergy; 2012 Feb; 67(2):280-5. PubMed ID: 22070352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastrointestinal digestion of Bet v 1-homologous food allergens destroys their mediator-releasing, but not T cell-activating, capacity.
    Schimek EM; Zwölfer B; Briza P; Jahn-Schmid B; Vogel L; Vieths S; Ebner C; Bohle B
    J Allergy Clin Immunol; 2005 Dec; 116(6):1327-33. PubMed ID: 16337467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
    Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
    Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
    Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
    J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1.
    Visco V; Dolecek C; Denépoux S; Le Mao J; Guret C; Rousset F; Guinnepain MT; Kraft D; Valenta R; Weyer A; Banchereau J; Labecque S
    J Immunol; 1996 Jul; 157(2):956-62. PubMed ID: 8752951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
    Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
    J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of IgE-binding to Art v 1, Art v 4 and Amb a 1 in mugwort-allergic patients.
    Oberhuber C; Ma Y; Wopfner N; Gadermaier G; Dedic A; Niggemann B; Maderegger B; Gruber P; Ferreira F; Scheiner O; Hoffmann-Sommergruber K
    Int Arch Allergy Immunol; 2008; 145(2):94-101. PubMed ID: 17823540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of immunotherapy using various updosing schedules of a new SCIT product with an optimised allergen/aluminium hydroxide ratio.
    Jung K
    Allergy; 2011 Jul; 66 Suppl 95():41-3. PubMed ID: 21668852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular and immunologic characterization of a highly cross-reactive two EF-hand calcium-binding alder pollen allergen, Aln g 4: structural basis for calcium-modulated IgE recognition.
    Hayek B; Vangelista L; Pastore A; Sperr WR; Valent P; Vrtala S; Niederberger V; Twardosz A; Kraft D; Valenta R
    J Immunol; 1998 Dec; 161(12):7031-9. PubMed ID: 9862740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy.
    Mittag D; Akkerdaas J; Ballmer-Weber BK; Vogel L; Wensing M; Becker WM; Koppelman SJ; Knulst AC; Helbling A; Hefle SL; Van Ree R; Vieths S
    J Allergy Clin Immunol; 2004 Dec; 114(6):1410-7. PubMed ID: 15577846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study.
    Höiby AS; Strand V; Robinson DS; Sager A; Rak S
    Clin Exp Allergy; 2010 Jul; 40(7):1062-70. PubMed ID: 20642579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio.
    Pfaar O; Jung K; Wolf H; Decot E; Kleine-Tebbe J; Klimek L; Wüstenberg E
    Allergy; 2012 May; 67(5):630-7. PubMed ID: 22385366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study.
    Bussmann C; Maintz L; Hart J; Allam JP; Vrtala S; Chen KW; Bieber T; Thomas WR; Valenta R; Zuberbier T; Sager A; Novak N
    Clin Exp Allergy; 2007 Sep; 37(9):1277-85. PubMed ID: 17845407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients.
    Ebner C; Schenk S; Najafian N; Siemann U; Steiner R; Fischer GW; Hoffmann K; Szépfalusi Z; Scheiner O; Kraft D
    J Immunol; 1995 Feb; 154(4):1932-40. PubMed ID: 7530747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.